In this episode of The HemOnc Pulse, Dr. Omar Nadeem of Dana-Farber Cancer Institute discusses how genomic data are reshaping the understanding of smoldering myeloma. He explains why traditional risk models may fall short and how molecular insights could guide earlier, more precise intervention. “We’re really left with more disease-burden-based risk stratification tools,” Dr. Nadeem notes, “but not necessarily any of the genomic data that tell us what’s happening underneath the hood.”

Dr. Rahul Banerjee interviews Dr. Ajay Major on patient-reported outcomes, toxicity reporting, and patient engagement in blood cancer clinical trials.

Dr. Gaby Hobbs joins the podcast to discuss the latest advances in myeloproliferative neoplasms (MPNs), including ropeginterferon and the VERIFY trial of rusfertide in polycythemia vera. He highlights key efficacy and safety data, unmet needs in essential thrombocythemia and myelofibrosis, and the next wave of clinical trials to watch.

Rahul Banerjee, MD interviews Drs. Schjesvold and Askeland on new myeloma trial data, enrollment of elderly patients, and the importance of inclusive, investigator-driven research.

MD Anderson fellows discuss AML, MRD endpoints, and evolving trial strategies in a dynamic grand rounds–style presentation.

Listen to Dr. William Wierda discuss the modern management of CLL.

Blood Cancers Today interviews Dr. Hira Mian during an Editor’s Special Episode.

Expert panel at The HemOnc Pulse Live event discuss the evolution of ALL treatment.

An Editor’s Special Episode featuring Andrew Brunner, MD

Panel of experts led by Naval Daver, MD discusses mutation loss, minimal residual disease, and transplant timing in AML treatment.

Drs. Gurbakhash Kaur and Danai Dima discuss next-gen CAR T and bispecific therapies for myeloma, including agents for extramedullary disease and GPRC5D targets.

This special episode explores major updates in B-cell non-Hodgkin lymphoma treatment from ASCO 2025, including advances in targeted therapies, evolving approaches to drug sequencing, and the impact of novel combinations across subtypes like CLL, follicular, mantle cell, and large B-cell lymphoma.

Dr. Alexey Danilov discusses key challenges in CLL treatment and highlights emerging therapies, including BTK degraders.

Saad Usmani, MD, MBA leads an in-depth discussion with a panel of leading myeloma experts; Dr. Caitlin Costello, Dr. Binod Dhakal, Dr. Pete Voorhees, and Dr. Shambavi Richard on the evolving landscape of frontline multiple myeloma treatment. The conversation covers the rationale behind quadruplet therapy, the integration of minimal residual disease as a response-adaptive strategy, and shifting perspectives on transplant eligibility and timing. Drawing on recent clinical trial data and personal clinical experience, the panel explores how these advancements are influencing treatment decisions and improving long-term outcomes for patients with newly diagnosed myeloma.

ASCO 2025 insights: Dr. Amir Fathi on oral AML regimens, triplet therapies & future treatment trends.

In this episode of The Hem Onc Pulse, Dr. Rahul Banerjee is joined by Dr. Michelle Longmire, CEO and co-founder of Medable, for a compelling discussion on drug accessibility in cancer care. Together, they explore how decentralized clinical trials and digital tools can help bridge the gap between cutting-edge therapies and the patients who need them most. Dr. Longmire shares how Medable is expanding access to clinical research, particularly in rural and underserved communities, by reimagining how trials are conducted. The conversation also examines the systemic and financial challenges that often prevent patients from accessing approved cancer therapies—even after regulatory success. With an eye toward equity, Drs. Banerjee and Longmire unpack the barriers in traditional oncology care and highlight innovative, patient-centered approaches that promise a more inclusive future. Tune in for a thought-provoking look at the intersection of innovation, policy, and compassion in cancer treatment access.

In this HemOnc Pulse Live! episode, Mehdi Hamadani, MD, leads a panel of experts in a focused discussion on key controversies in treating aggressive non-Hodgkin lymphoma.

In this episode of HemOnc Pulse, host Rahul Banerjee, MD, FACP of Fred Hutch Cancer Center is joined by myeloid malignancy expert Uma Borate, MBBS of The Ohio State University, for a high-impact discussion on one of hematology’s hottest frontiers: early detection. As aggressive diseases like AML and MDS continue to outpace traditional diagnostics, this conversation dives into why spotting these cancers sooner isn’t just helpful—it’s lifesaving.  

A HemOnc Pulse Live episode featuring Naval Daver, MD of MD Anderson Cancer Center and panel of other expert in myelodysplastic syndromes.

In this episode of The HemOnc Pulse, Rahul Banerjee, MD of Fred Hutchinson Cancer Center is joined by Gurbakhash Kaur, MD of Mount Sinai for an in-depth discussion of the RedirecTT-1 trial.